The following study has recently been activated for patient enrollment by the University of Illinois Cancer Center Clinical Trials Office (CTO). Please click on the link to learn about the details regarding the study on clinicaltrials.gov. For more information or questions about a study, please email email@example.com or call 312-355-5112.
NRG-GU008: Randomized Phase III Trial Incorporating Abiraterone Acetate With Prednisone and Apalutamide and Advanced Imaging Into Salvage Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy
Sponsor: NRG Oncology
Collaborator: National Cancer Institute
Principal Investigator: Daniel Moreira, MD